I am genuinely confused here.  As I understood things Futility Analysis of 2 stage 3 trials resulted in the trials being halted for lack of efficacy....the drug wasn't going to meet its primary endpoint.  Now there's news saying that Biogen is saying they did meet the primary endpoint, with trials that were halted???

So aducanumab could have met the primary endpoint with basically half of the trials being completed?

If that is the case it does raise my hopes for BETonMACE's primary endpoint results, notwithstanding the annoucement of failure.  This is like Bizarro world.